|
Published by: Espicom Healthcare Intelligence
Published: May. 31, 2007 - 100 Pages
Table of Contents
- Volume 1
- EXECUTIVE SUMMARY
- BREAST CANCER
- THE FACTS
- PATIENT STATISTICS
- PATIENT MODEL
- THE MARKET
- GLOBAL CANCER MARKET
- THE BREAST CANCER MARKET
- THE PLAYERS
- CURRENT TREATMENTS
- CHEMOTHERAPY
- TARGETED THERAPY
- RESEARCH & DEVELOPMENT OF BC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- APPENDIX 7
- GLOSSARY
- BIBLIOGRAPHY
- WEBSITE REFERENCES
- ACRONYMS
- COLORECTAL CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- THE CRC MARKET
- CURRENT TREATMENTS
- CHEMOTHERAPY
- IMMUNOTHERAPY
- RESEARCH & DEVELOPMENT OF CRC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- COMPETITOR RATIO ANALYSIS - COMPANIES
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- BIBLIOGRAPHY
- ACRONYMS
- Volume 2
- NON-SMALL CELL LUNG CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- THE NSCLC MARKET
- RESEARCH & DEVELOPMENT OF NSCLC DRUGS
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF NSCLC DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- BIBLIOGRAPHY
- GLOSSARY
- ACRONYMS
- PROSTATE CANCER
- THE FACTS
- GLOBAL CANCER MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
- APPENDIX 4
- APPENDIX 5
- APPENDIX 6
- GLOSSARY
- REFERENCES
- ACRONYMS
- RENAL CELL CARCINOMA
- THE FACTS
- THE MARKET
- COMPETITOR RATIO ANALYSIS - PRODUCTS
- DISCONTINUATION OF DRUGS
- APPENDIX 1
- APPENDIX 2
- APPENDIX 3
AbstractProstate cancer is the second leading cause of cancer in the US and the third most common cancer worldwide. More than two million men in the US suffer with prostate cancer. Find out more about market developments in this chapter of Cancer Drug Discoveries.
Key questions answered include:
- The patient population suffering from PCA is increasing at 4.8% per year. What clinical and sociological factors are influencing this?
- What are the strengths and weaknesses of Dendreon’s Provenge and Cell Genesys’ GVAX and which is likely to dominate?
- What pipeline products will AstraZeneca introduce to maintain its leading position in the PCA market despite generic competition to Casodex (2008) and Zoladex (2011)?
Get Full Details About This Report >>
|
